Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, Guangdong, China.
Biosci Rep. 2021 Feb 26;41(2). doi: 10.1042/BSR20204043.
Several studies on the prognostic value of microRNA 142 (miR-142) in solid tumors have reported conflicting results. Therefore, the aim of this meta-analysis was to evaluate the relationship between the miR-142 and prognosis in solid tumors. A comprehensive search for relevant studies was conducted until 10 November 2020. Studies that investigated the prognostic significance of the miR-142 in solid tumors were included. The hazard ratio and 95% confidence interval were calculated using a random-effects model. All data analyses were performed using the STATA 12.0 software (Stata Corporation, College Station, TX, U.S.A.). Twenty articles involving 2451 participants were included in the meta-analysis. The results showed that high miR-142 expression was a better predictor of overall survival (OS) (HR = 0.66, 95% CI: 0.47-0.93) and disease-free/progression-free/recurrence-free survival (DFS/PFS/RFS) (HR = 0.71, 95% CI: 0.55-0.91) compared with low miR-142 expression. MiR-142 can be used as an effective prognostic marker for patients with solid tumors. Future large prospective studies are warranted to further confirm the present findings.
已有多项关于 microRNA 142（miR-142）在实体瘤中预后价值的研究得出了相互矛盾的结果。因此，本荟萃分析旨在评估 miR-142 与实体瘤预后之间的关系。我们全面检索了截至 2020 年 11 月 10 日的相关研究。纳入了探讨 miR-142 在实体瘤中预后意义的研究。使用随机效应模型计算了风险比（HR）和 95%置信区间（CI）。所有数据分析均使用 STATA 12.0 软件（Stata Corporation，College Station，TX，USA）进行。荟萃分析纳入了 20 项研究，共 2451 名参与者。结果表明，miR-142 高表达与总生存期（OS）（HR = 0.66，95%CI：0.47-0.93）和无病/无进展/无复发生存期（DFS/PFS/RFS）（HR = 0.71，95%CI：0.55-0.91）的改善相关。miR-142 可作为实体瘤患者的一种有效预后标志物。需要进一步开展大型前瞻性研究来验证本研究结果。
